Vascular Surgery Brochure

Vascular
Surgery
Portfolio

Providing a unique offering
of revolutionary grafts
and proactive haemostasis
solutions to the field of vascular
surgery in the UK.

Our Partners

Our Partners >

BioIntegral Surgical > Aquilant, now a Healthcare21 company, has been a longstanding supplier of vascular
solutions within the Interventional market for more than 10 years. Working with some of
Infection Resistance the most innovative, market-leading manufacturers we now step into the Vascular Surgery
arena where we continue to deliver the very best in medical devices and procedural support
Biomodified Grafts > to our customers in the UK.

Order Information > With over 20 years of experience, BioIntegral Surgical, Inc. are focused on all-biological
cardiovascular implants designed to both enhance outcomes and reduce complications in
Haemostasis > critical care, paediatric and adult patients.

Contact > Balancing durable designs, quick implantation, and biocompatible materials, they aim
to eliminate the ordinary compromises and shortcomings of alternative products. Their
devices utilize permanently-fixed tissue, and avoid synthetic materials, leaching of toxic
residuals, and cheap-to-manufacture designs resulting in compromised redistribution of
force and longevity.

Headquartered in Tokyo, Japan, 3-D Matrix is a medical device company that offers
innovative peptide technology, revolutionising the way healthcare professionals manage
oozing bleeding during surgery.

With a well-established haemostat in the UK endoscopy market, as well as existing
collaborations across Cardiovascular, Gynaecology and ENT, 3-D Matrix now introduce a
unique means of treating bleeding sites to vascular applications.

BioIntegral Surgical

Why >

How >

What > REVOLUTIONISING THE TREATMENT
OF INFECTED GRAFTS AND BEYOND

What’s next > With over 10,000 implants and 20 years of data in the cardiac
sector, BioIntegral surgical expanded into manufacturing
Feedback > vascular grafts in response to demand from their existing users.

Now, 5 years on, they have thoracic, bifurcated, and peripheral
vascular grafts with over 500 implants in Europe.

Ethos > Thoracic Grafts Peripheral Grafts Bifurcated Grafts

Contact >

DOWNLOAD FAQ’s

Infection Resistance

Why > Infection Resistance What’s the secret?
What’s the difference? A Monolayer of
How >
THE FIRST FULLY-LICENSED BIOMODIFIED, endothelium on all
BOVINE PERICARDIUM GRAFTS IN THE UK blood contacting

surfaces

What >

What’s next > The BioIntegral Surgical Technology

Feedback > The BioIntegral Surgical biomodified technology functions to allow growth
of the endothelium on all blood contacting surfaces.
Ethos >
• Reduced toxicity
Contact > • Enhanced biocompatibility
• Lower rates of infections, adhesions and calcifications1
• Allows for endothelialization, thus enhances patency better
than any other vascular graft

DOWNLOAD BIFURCATED GRAFT BROCHURE
DOWNLOAD BIOINTEGRAL IFU

1. Yerebakan, C., et al., “Long-term results of
biventricular repair after initial Giessen hy- brid
approach for hypoplastic left heart variants,” J. Thor.
Card. Surg. 149 (2015).

Biomodified Grafts

Why > Biomodified Grafts

How > WHY CHOOSE BIOINTEGRAL?

What > A Totally Biological Perima™ and Perima™ Bifurcation

What’s next > Ease of Use Vigorous Safety Testing Multiple Indications Enhanced Fully Licensed
No preparation Bicompatibility
Feedback > Burst Pressure up to Thoratic, bifucated The only CE marked
required 1900mmHg and peripheral grafts Lower rate of bovine pericardium
4-year shelf life infections, adhesions graft on the market
High tensile/pull Large range of sizes
strength available for various and calcifications

Ethos > indications

Contact > • Clinical experience with over 400 patients and 9000 BioConduit implants, prove resistance to infection
at least as good as the autogenous vein1,2,3

• Overwhelming results show resistance to stenosis, calcification, dilatation, and thrombosis

• Made from bovine pericardium for superior strength

• Substitute for replacing vascular bifurcated grafts or tissue in patients with infection or at high risk
of infection

• Saves 3 to 4 hours in tailoring the autogenous bifurcation (see complete clinical manual)

1. Amir Aboholda, et al., “No-React Detoxification DOWNLOAD Clinical Evidence – Paper 1 – Burgbuber et al.
Process: A Superior Anticalcification Method for DOWNLOAD Clinical Evidence – Paper 2 – Rojas et al.
Bioprostheses.” Ann. Thor. Surg. 62 (1996) 1724-30.

2. Michele Musci, et al. “Surgical therapy in patients
with active infective endocarditis: sev- en-year single
centre experience in a subgroup of 255 patients
treated with the Shelhigh stentless bioprosthesis,”
Eur. J. Card. Surg. 34 (2008) 410-417.

3. Michele Musci, et al. “Further Experience with the
“No-React” Bioprosthesis in Patients with Active
Infective Endocarditis: 11-Year Single Center Results
in 402 Patients”
Eur. J. Card. Surg. 61 (2013) 398-408.

Order information

Why > Order information

How > With bifurcated, thoracic and peripheral vascular grafts, as
well as patches, BioIntegral offer a complete solution for every
procedure.

What > Thoracic Grafts Peripheral Grafts Bifurcated Grafts
& Patches

What’s next >

Feedback >

Ethos >

Contact > • Unique Offering
• 0.5mm Bovine Pericardium
• Hand crafted with polyester sutures
• Wide range of sizes and lengths
• Robust manufacturing process and quality testing process

DOWNLOAD BioIntegral Ordering information

Haemostasis

Why >

How >

What > PURABOND

What’s next > Why choose PuraBond?
Purabond is a synthetic, peptide-based haemostat in a
Feedback > pre-prepared syringe.

Ethos > PuraBond is indicated when haemostasis by ligation or standard
means is insufficient or impractical1, such as:

• Bleeding from small blood vessels and oozing from capillaries of the
parenchyma of solid organs

• Oozing from vascular anastomoses

Contact > NO DOES NOT MIMICS
PREPARATION SWELL HUMAN ECM
TRANSPARENT

REVOLUTIONARY SYNTHETIC REAPPLICABLE SUITA BILIT Y
BLEEDING AND
CONTROL
RESORBABLE

1. Morshuis M, Final Clinical Study Report: A Single- VIDEO Purabond
Centre, Single Arm Post-Market Clinical Follow-Up DOWNLOAD Purabond IFU
to Confirm the Safety and Performance of DOWNLOAD Purabond Vascular Indications and Ordering Information
PuraStat Absorbable Haemostatic Material for the DOWNLOAD Purabond Case Study
Management of Bleeding After Left Ventricular
Assist Device (LVAD) Implantation

Contact

Why > Team Contact details

How > James Hillcoat
Wales & West England
What > M: +44 7342 055 736
[email protected]
What’s next > UK:
+44 (0) 1256 306 506
Feedback > Laura Young Ireland:
Scotland & North England +353 (0) 21 487 5055
Ethos > M: +44 7900 561 487
[email protected] UK Head Office
Contact > Unit B1-B2, Bond Close
Jason Cardwell Kingsland Business Park
Midlands & East England Basingstoke
M: +44 7711 369 359 Hampshire RG24 8PZ
[email protected]
Irish Head Office
Gary Hobbs Unit 5, Westpoint Buildings
London & Essex Westpoint Business Park
M: +44 7900 562 565 Ballincollig
[email protected] Cork

Steve Matthews healthcare21.eu
National Sales Manager E: [email protected]
M: +44 7887 528 566